Sylentis Sees Phase III Trial for Glaucoma Drug by 2015 | GenomeWeb

With positive phase II data on its siRNA-based glaucoma treatment in hand, Spanish RNAi drug developer Sylentis is preparing to move into phase IIb study next year, with a pivotal trial possible by 2015, according to a company official.

Meanwhile, Sylentis is on track to complete enrollment for a phase I/II study of a treatment for pain associated with dry eye syndrome by year-end and release data shortly thereafter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.